Back to Search
Start Over
The Current Treatment Landscape of Cutaneous Squamous Cell Carcinoma.
- Source :
- American Journal of Clinical Dermatology; Jan2023, Vol. 24 Issue 1, p25-40, 16p
- Publication Year :
- 2023
-
Abstract
- Non-melanoma skin cancers (NMSCs) are the most common form of skin cancer worldwide. The global incidence of cutaneous squamous cell carcinoma (CSCC) is rising, with an estimated 2.4 million cases diagnosed in 2019. Chronic exposure to ultraviolet (UV) radiation is a major risk factor for developing CSCC. Most early-stage CSCCs are treated successfully with surgery or radiotherapy; however, locally advanced or metastatic disease can be associated with significant morbidity or mortality. Recently, the treatment paradigm for advanced CSCC has been revolutionised by the introduction of immunotherapy, which can achieve a response rate of approximately 50% with durable cancer control, and significant improvement in quality of life. With the regulatory approval of programmed death-1 (PD-1)-targeting drugs since 2018, immunotherapy is now recognised as the standard of care for first-line systemic therapy in advanced or metastatic CSCC. [ABSTRACT FROM AUTHOR]
- Subjects :
- THERAPEUTIC use of monoclonal antibodies
THERAPEUTIC use of antineoplastic agents
CHRONIC lymphocytic leukemia
ADJUVANT chemotherapy
IMMUNE checkpoint inhibitors
GENETIC mutation
INFLAMMATION
CHRONIC diseases
CANCER chemotherapy
METASTASIS
PATIENTS
SKIN tumors
INTERFERONS
PAPILLOMAVIRUS diseases
COMBINED modality therapy
TUMOR markers
SQUAMOUS cell carcinoma
IMMUNOTHERAPY
ENVIRONMENTAL exposure
ULTRAVIOLET radiation
TRANSPLANTATION of organs, tissues, etc.
DISEASE risk factors
Subjects
Details
- Language :
- English
- ISSN :
- 11750561
- Volume :
- 24
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- American Journal of Clinical Dermatology
- Publication Type :
- Academic Journal
- Accession number :
- 161448819
- Full Text :
- https://doi.org/10.1007/s40257-022-00742-8